<table class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td style="text-align: center;"><a href="http://3.bp.blogspot.com/-jfbWgrplfaU/VFuS4CaFc-I/AAAAAAAADIA/LdW1wE6PyeE/s1600/Misconceptions.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img src="http://3.bp.blogspot.com/-jfbWgrplfaU/VFuS4CaFc-I/AAAAAAAADIA/LdW1wE6PyeE/s1600/Misconceptions.jpg" height="188" border="0" width="200" /></a></td>
</tr>
<tr>
<td class="tr-caption" style="text-align: center;"> http://andreyev.com.au/wp-content/uploads/Misconceptions.jpg</td>
</tr>
</tbody>
</table>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 0in; mso-add-space: auto;"><span style="font-family: 'Arial',sans-serif;">We blogged recently about </span><a href="http://roosterbio.blogspot.com/2014/10/current-bottlenecks-in-msc-research.html"><span style="font-family: 'Arial',sans-serif;">Mesenchymal Stem/Stromal Cell (MSC) Misconceptions</span></a><span style="font-family: 'Arial',sans-serif;"> that are holding the translational cell therapy field back, as identified by </span><a href="http://www.scripps.edu/florida/philanthropy/action/phinney-profile.html"><span style="font-family: 'Arial',sans-serif;">Donald Phinney</span></a><span style="font-family: 'Arial',sans-serif;"> and </span><a href="http://www.stromalab.fr/index.php?option=com_content&amp;view=article&amp;id=86&amp;lang=en"><span style="font-family: 'Arial',sans-serif;">Luc Sensebé</span></a><span style="font-family: 'Arial',sans-serif;">. Since we have come to market with our own hMSC product lines, we have spoken with hundreds of MSC researchers and engineers, and we have compiled our own...</span></div> Read More

We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cellsthat are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in...
Read More

Mesenchymal stem cells (MSCs)aggregated into three-dimensional (3D) cellular spheroids are a potent configuration for cell therapy and tissue engineering research and product development (5), and cellular spheroids are a preferred format for many bioprinting applications (10). Cellular spheroids are essentially micro-tissues that can be manufactured as standardized “living materials” with certain...
Read More
Last week was the 4th Annual IBC Cell Therapy Bioprocessing Conference. IBC (home of the BioProcess International conference) was the first conference organizer to dedicate a focused meeting on Cell Therapy Manufacturing Technologies 4 years ago. Since the first conference in 2011, the growth in the field, and the conference, has been amazing. The attendance has grown from less than 90 in year 1...
Read More
From www.CellTherapyWonk.com
Fall is almost here, and that means it is Cell Therapy BioProcessing and Manufacturing conference season. This year it started a few weeks earlier as conference organizer CHI put together a Cell Therapy BioProduction session as part of their Annual BioProcessing Summit in Boston from August 18-22. In our last post (Scale-up Production – Post 1 of 2), I summarized some...
Read More
Closed system 10 layer and media bags are
now readilyavailable from several vendors.
Fall is almost here, and that means it is Cell Therapy BioProcessing and Manufacturing conference season. This year, it started a few weeks earlier as conference organizer CHI put together a Cell Therapy BioProduction session as part of their Annual BioProcessing Summitin Boston from August 18-22. It is always...
Read More
Human MSCs are the single most used cell source for tissue engineering and regenerative medicine applications, and clinical trials involving hMSCs have outpaced all other cell types in recent years (see hereand here). However, despite indications of clinical effectiveness (see here and here), there is repeated news of the failure of high-profile MSC trials to demonstrate efficacy in a number of...
Read More
There has been much discussion in the literature and the blogosphere (here, here, and here) lately about keeping track of cellular age, and there is very good reason for this. First, there are multiple regulatory guidelines that propose tracking the age of cells used in biologics manufacturing. Secondly, it is well documented that cell phenotype and function can be compromised the older a cell is.... Read More
MSCs truly are the Workhorse of Regenerative Medicine, and their use in Orthopaedic applications is where clinical translation was initially imagined. However, the robust signaling activityof MSCs has widened the range of clinical indications to include cardiac, vascular, and neurological regeneration, as well as immunological applications (eg. GVHD, Chron’s disease), and more recently, cancer...
Read More
Extreme cellular stress can trigger senescence, a mechanism protecting
against malignant cell transformation.
Adapted from:
Kovacic J C et al. Circulation. 2011;123:1650-1660
We’ve mentioned several times on this blog how standardizationof materials, equipment and processes is critical to driving reproducibility and robustness of living cell technologies. As we continue to engage researchers in...
Read More